Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology

What Vaccines Do Primary Ciliary Dyskinesia Patients Need?

At a Glance

Children and adults with Primary Ciliary Dyskinesia (PCD) require an expanded vaccination schedule to protect their lungs. Key vaccines include pneumococcal, flu, COVID-19, RSV, and Tdap to prevent severe respiratory infections and permanent airway damage from trapped mucus.

In this answer

3 sections

01

Why Vaccines Matter More in PCD

02

Essential Lung-Protecting Vaccines for PCD

03

Protecting the Home Environment

Children and adults with Primary Ciliary Dyskinesia (PCD) require the standard vaccination schedule, plus several critical, expanded vaccines designed specifically to protect their vulnerable lungs. Because PCD impairs the lungs’ ability to clear out mucus and germs, routine respiratory infections can quickly escalate into severe pneumonias. Ensuring you or your child is up-to-date on specific vaccines—especially for pneumococcus, influenza, COVID-19, and RSV—is a foundational part of daily preventative care.

Why Vaccines Matter More in PCD

In a healthy respiratory system, tiny hair-like structures called cilia sweep mucus, dust, and bacteria out of the airways. In PCD, these cilia are defective or do not move properly, which leads to impaired mucociliary clearance [1][2]. This causes mucus to stagnate in the lungs, creating a perfect environment for recurrent bacterial and viral infections [1].

Without aggressive preventative management, repeated cycles of infection and inflammation can lead to bronchiectasis—a condition where the airways become widened, flabby, and permanently scarred [3][1]. Preventing severe lung infections through vaccination is one of the most effective ways to delay respiratory decline and protect long-term lung function [3][4].

Essential Lung-Protecting Vaccines for PCD

Because large-scale clinical trials specifically for PCD are difficult to conduct, medical guidelines for managing the disease are often adapted from those for cystic fibrosis and other chronic lung diseases [5][6]. However, major health authorities consider children and adults with chronic lung diseases to be “high-risk,” which qualifies them for enhanced vaccination schedules [7].

1. Pneumococcal Vaccines

Streptococcus pneumoniae (pneumococcus) is a common bacterium that can cause severe pneumonia. Because patients with PCD are considered high-risk, they require an expanded pneumococcal vaccination schedule [8].

  • Conjugate Vaccines (PCV): Patients should receive newer, higher-valent conjugate vaccines like PCV15 or PCV20, which cover more bacterial strains [9].
  • Polysaccharide Vaccine (PPSV23): Depending on which conjugate vaccine is used, additional protection may be needed. For example, individuals who receive PCV15 typically require a follow-up dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for broader protection, whereas those receiving PCV20 may not need the PPSV23 dose [10][11]. Your doctor will determine the exact sequence based on your age and vaccine history.

2. Annual Influenza (Flu) Vaccine

The flu is not just a heavy cold; it is a serious viral infection that damages the airway lining, making it much easier for dangerous bacteria to invade and colonize the lungs. An annual flu shot is strongly recommended to reduce the risk of severe respiratory complications [12].

3. COVID-19 Boosters

Like influenza, COVID-19 poses a significant risk to individuals with compromised lung function. Staying up-to-date with current COVID-19 boosters is a safe, well-tolerated, and critical step in preventing viral pneumonia [13][14]. It is safe and common practice to receive the seasonal influenza vaccine and the COVID-19 booster at the same time [13].

4. RSV Prevention (For Infants and Adults)

Respiratory Syncytial Virus (RSV) is a common virus that can be devastating for those with chronic lung conditions [15].

  • For Infants: Infants with PCD are particularly vulnerable to early-life lung damage. Protection can be achieved through maternal RSV vaccination during pregnancy or by administering a preventive medication (like nirsevimab) directly to the infant [16][17].
  • For Adults: Older adults (typically aged 60 and older) with chronic lung diseases like PCD are at an increased risk for severe RSV hospitalizations [18]. Dedicated RSV vaccines are now available for older adults, and you should discuss receiving this vaccine with your pulmonologist.

5. Tdap (Whooping Cough)

The Tdap vaccine protects against tetanus, diphtheria, and pertussis (whooping cough). Whooping cough is characterized by thick, heavy secretions and violent coughing fits, which are exceptionally dangerous for individuals who already struggle to clear mucus from their airways. Ensure you or your child’s Tdap boosters are current.

Protecting the Home Environment

Vaccinating the person with PCD is only half the battle. To minimize exposure to infectious diseases, it is highly recommended that all family members and close household contacts stay up to date on their own routine vaccinations, including flu shots, COVID-19 boosters, and Tdap [19].

This strategy, known as cocooning, creates a protective barrier around the vulnerable individual [20][21]. By ensuring everyone in the household is immunized, you significantly reduce the chance that a severe respiratory virus or bacteria is brought into the home [19]. Because guidelines and age-based approvals change frequently, be sure to ask your pulmonologist to review your specific high-risk immunization schedule at least once a year.

Common questions in this guide

Why are vaccines especially important for someone with PCD?
People with PCD have defective cilia that cannot effectively clear mucus from the lungs. This trapped mucus creates an ideal environment for recurrent infections, making preventative vaccines essential to protect long-term lung function and delay respiratory decline.
Which pneumococcal vaccines do PCD patients need?
Because PCD patients are considered high-risk, they require an expanded pneumococcal vaccination schedule. This typically involves newer conjugate vaccines like PCV15 or PCV20, which may be followed by the PPSV23 vaccine for broader protection against bacterial pneumonia.
Should infants with PCD receive the RSV vaccine?
Yes, infants with PCD are highly vulnerable to early-life lung damage from Respiratory Syncytial Virus (RSV). Protection can be provided through maternal vaccination during pregnancy or by giving the infant a preventive medication directly.
What does cocooning mean in PCD care?
Cocooning involves ensuring all family members and close household contacts are up-to-date on their routine vaccinations. This creates a protective barrier that reduces the chances of bringing severe respiratory viruses or bacteria into the home where the PCD patient lives.
How does the Tdap vaccine help patients with PCD?
The Tdap vaccine protects against whooping cough, an infection that causes thick secretions and violent coughing fits. These symptoms are exceptionally dangerous for someone who already struggles to clear mucus from their airways.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific sequence of pneumococcal vaccines (PCV15, PCV20, or PPSV23) do you recommend for my current age and medical history?
  2. 2.Do I qualify for the RSV vaccine based on my age and lung function, and when is the best time of year to receive it?
  3. 3.How long has it been since my last Tdap booster, and is it time for another one to ensure I am protected against whooping cough?
  4. 4.How often should we review and update my high-risk immunization schedule?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are Ear Tubes Safe for Children With PCD?Can CF Medications Treat Primary Ciliary Dyskinesia?Can You Have PCD With Normal Biopsy and nNO Tests?Is My Child's Cough PCD or a Normal Daycare Cold?Does Primary Ciliary Dyskinesia Cause Infertility?How is PCD Diagnosed in Babies and Toddlers?Is Sinus Surgery Effective for Primary Ciliary Dyskinesia?Will I Need a Lung Transplant for PCD or Kartagener's?What is Secondary vs Primary Ciliary Dyskinesia?What Do CCDC39 & CCDC40 Mutations Mean for PCD Prognosis?What is the Life Expectancy for PCD?

References

References (21)
  1. 1

    The challenge of diagnosing primary ciliary dyskinesia: a commentary on various causative genes and their pathogenic variants.

    Keicho N, Morimoto K, Hijikata M

    Journal of human genetics 2023; (68(8)):571-575 doi:10.1038/s10038-023-01166-w.

    PMID: 37277434
  2. 2

    Primary ciliary dyskinesia: mechanisms and management.

    Damseh N, Quercia N, Rumman N, et al.

    The application of clinical genetics 2017; (10()):67-74 doi:10.2147/TACG.S127129.

    PMID: 29033599
  3. 3

    NO way! Nasal nitric oxide measurement in infants.

    Lucas JS, Walker WT

    The European respiratory journal 2018; (51(6)) doi:10.1183/13993003.00958-2018.

    PMID: 29929961
  4. 4

    Primary Ciliary Dyskinesia-Current Diagnostic and Therapeutic Approach.

    Wrona J, Krupa Z, Zawadzka M, et al.

    Journal of clinical medicine 2025; (14(19)) doi:10.3390/jcm14196808.

    PMID: 41095888
  5. 5

    Primary ciliary dyskinesia: a national expert consensus statement on standards of care.

    Robson EA, Spoletini G, Bercusson A, et al.

    ERJ open research 2026; (12(1)) doi:10.1183/23120541.00466-2025.

    PMID: 41561099
  6. 6

    Clinical care of children with primary ciliary dyskinesia.

    Lucas JS, Alanin MC, Collins S, et al.

    Expert review of respiratory medicine 2017; (11(10)):779-790 doi:10.1080/17476348.2017.1360770.

    PMID: 28745925
  7. 7

    Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics.

    Harris JG, Harris LA, Olarte L, et al.

    Pediatrics 2022; (149(4)) doi:10.1542/peds.2020-031724.

    PMID: 35233616
  8. 8

    Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate vaccine use among children in the United States.

    Ayabina D, Stoecker C, Cho BH, et al.

    Vaccine 2026; (74()):128212 doi:10.1016/j.vaccine.2026.128212.

    PMID: 41564611
  9. 9

    The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era.

    Chen CH, Chen CL, Su LH, et al.

    Human vaccines & immunotherapeutics 2025; (21(1)):2497611 doi:10.1080/21645515.2025.2497611.

    PMID: 40289536
  10. 10

    Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

    Kobayashi M, Farrar JL, Gierke R, et al.

    MMWR. Morbidity and mortality weekly report 2022; (71(4)):109-117 doi:10.15585/mmwr.mm7104a1.

    PMID: 35085226
  11. 11

    Burden of Lower Respiratory Tract Infections Preventable by Adult Immunization With 15- and 20-Valent Pneumococcal Conjugate Vaccines in the United States.

    Lewnard JA, Hong V, Bruxvoort KJ, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; (77(9)):1340-1352 doi:10.1093/cid/ciad355.

    PMID: 37293708
  12. 12

    Flu vaccine administration in the period before SARS-CoV-2 infection and its outcomes: An umbrella review.

    Angeletti PM, Marchi S, Trombetta CM, Altobelli E

    Preventive medicine reports 2024; (38()):102575 doi:10.1016/j.pmedr.2023.102575.

    PMID: 38283956
  13. 13

    No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.

    Naficy A, Kuxhausen A, Seifert H, et al.

    Human vaccines & immunotherapeutics 2024; (20(1)):2327736 doi:10.1080/21645515.2024.2327736.

    PMID: 38513689
  14. 14

    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.

    Moscara L, Venerito V, Martinelli A, et al.

    Vaccine 2023; (41(38)):5655-5661 doi:10.1016/j.vaccine.2023.07.043.

    PMID: 37544827
  15. 15

    Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis.

    McLaughlin JM, Khan F, Begier E, et al.

    Open forum infectious diseases 2022; (9(7)):ofac300 doi:10.1093/ofid/ofac300.

    PMID: 35873302
  16. 16

    Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.

    Moulia DL, Link-Gelles R, Chu HY, et al.

    MMWR. Morbidity and mortality weekly report 2025; (74(32)):508-514 doi:10.15585/mmwr.mm7432a3.

    PMID: 40880502
  17. 17

    Effectiveness of Nirsevimab in Preventing Respiratory Syncytial Virus-related Burden: A Test-negative Case-control Study in Infants With Bronchiolitis in Lombardy Region, Italy.

    Fusco E, Loiodice M, Romero A, et al.

    The Pediatric infectious disease journal 2026; (45(1)):e12-e14 doi:10.1097/INF.0000000000004968.

    PMID: 41104905
  18. 18

    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.

    Payne AB, Watts JA, Mitchell PK, et al.

    Lancet (London, England) 2024; (404(10462)):1547-1559 doi:10.1016/S0140-6736(24)01738-0.

    PMID: 39426837
  19. 19

    Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunity.

    Tan ST, Rodríguez-Barraquer I, Kwan AT, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.07.23.24310889.

    PMID: 39211889
  20. 20

    Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile.

    Mukherjee S, Ray SK

    Infectious disorders drug targets 2022; (22(4)):e170122200309 doi:10.2174/1871526522666220117153838.

    PMID: 35040409
  21. 21

    [Pertussis: Where do we stand 10years after the introduction of cocooning vaccination strategy in France?]

    Beaufils E, Dommergues MA, Gaillat J, et al.

    Gynecologie, obstetrique & fertilite 2016; (44(10)):591-597 doi:10.1016/j.gyobfe.2016.08.003.

    PMID: 27638230

This page provides general information about recommended vaccines for Primary Ciliary Dyskinesia. Always consult your pulmonologist to determine the exact immunization schedule right for you or your child.

Get notified when new evidence is published on Primary ciliary dyskinesia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.